Susan M. O'Brien MD

Articles

Dr. O'Brien on the Phase III ASCEND Trial in CLL

June 16th 2019

Susan M. O’Brien, MD, associate director for Clinical Services, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the phase III ASCEND trial in chronic lymphocytic leukemia.

Dr. O'Brien on CAR T Cells in CLL

November 15th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the potential for CAR T-cell therapy for the treatment of chronic lymphocytic leukemia.

Dr. O'Brien Discusses Duvelisib in CLL

September 18th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses the promise of duvelisib in the treatment landscape of chronic lymphocytic leukemia.

Dr. Susan O'Brien Compares Ibrutinib With Chemoimmunotherapy in Frontline CLL

August 11th 2016

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLL

June 19th 2015

Susan M. O'Brien, MD, associate director, Clinical Science Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, Chao Family Comprehensive Cancer Center, University of California at Irvine, discusses the use of ibrutinib and idealisib in chronic lymphocytic leukemia (CLL).

Dr. O'Brien Discusses the Standard of Care for CLL

January 22nd 2012

Dr. Susan O'Brien, from the MD Anderson Cancer Center, Discusses the Standard of Care for CLL